11 results on '"Hillon, P."'
Search Results
2. Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis.
- Author
-
Petit, J.‐M., Pedro, L., Guiu, B., Duvillard, L., Bouillet, B., Jooste, V., Habchi, M., Crevisy, E., Fourmont, C., Buffier, P., Hillon, P., Cercueil, J.‐P., and Verges, B.
- Subjects
TYPE 2 diabetes diagnosis ,CHOLESTEROL ,DIET ,GLOMERULAR filtration rate ,FATTY liver ,GLYCOSYLATED hemoglobin ,LIVER function tests ,TYPE 1 diabetes ,RESEARCH funding ,DATA analysis ,BODY mass index ,DESCRIPTIVE statistics ,DIAGNOSIS ,DISEASE risk factors - Abstract
Aim Non-alcoholic fatty liver disease (NAFLD) is commonly associated with Type 2 diabetes. Recently, it has been suggested that NAFLD is also frequently associated with Type 1 diabetes and diabetic complications. In this study, we set out to determine whether Type 1 diabetes was associated with liver fat content measured using magnetic resonance imaging. Methods One hundred and twenty-eight patients with Type 1 diabetes, 264 patients with Type 2 diabetes and 67 participants without diabetes were included in this study. Hepatic steatosis was defined as a liver fat content > 5.5%. Results People with Type 1 diabetes and controls were similar for age and BMI. Liver fat content was significantly higher in patients with Type 2 diabetes than in patients with Type 1 diabetes and controls. In the control group, nine people (13.4%) had steatosis compared with six (4.7%) patients with Type 1 diabetes (P = 0.04). Among patients with Type 2 diabetes group, 166 (62.8%) had steatosis. In multivariate analysis that included patients with Type 1 diabetes and participants without diabetes, steatosis was associated only with BMI, whereas age, sex, statin therapy and Type 1 diabetes were not. In patients with Type 1 diabetes, there was no correlation between liver fat content and estimated glomerular filtration rate or carotid intima media thickness. Conclusions Our data showed that Type 1 diabetes was not associated with an increased prevalence of steatosis. Moreover, our study provided no specific arguments concerning a link between liver fat content and diabetic complications in patients with Type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
- Author
-
Boulin, M., Hillon, P., Cercueil, J. P., Bonnetain, F., Dabakuyo, S., Minello, A., Jouve, J. L., Lepage, C., Bardou, M., Wendremaire, M., Guerard, P., Denys, A., Grandvuillemin, A., Chauffert, B., Bedenne, L., and Guiu, B.
- Subjects
- *
IDARUBICIN , *LIVER cancer , *CLINICAL trials , *CIRRHOSIS of the liver , *PHARMACOKINETICS , *QUALITY of life - Abstract
Background A phase I dose-escalation trial of transarterial chemoembolisation ( TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma ( HCC). Aim To estimate the maximum-tolerated dose ( MTD) and to assess safety, efficacy, pharmacokinetics and quality of life. Methods Patients received a single TACE session with injection of 2 mL drug-eluting beads (DEBs; DC Bead 300-500 μm) loaded with idarubicin. The idarubicin dose was escalated according to a modified continuous reassessment method. MTD was defined as the dose level closest to that causing dose-limiting toxicity (DLT) in 20% of patients. Results Twenty-one patients were enrolled, including nine patients at 5 mg, six patients at 10 mg, and six patients at 15 mg. One patient at each dose level experienced DLT (acute myocardial infarction, hyperbilirubinaemia and elevated aspartate aminotransferase ( AST) at 5-, 10- and 15-mg, respectively). The calculated MTD of idarubicin was 10 mg. The most frequent grade ≥3 adverse events were pain, elevated AST, elevated γ-glutamyltranspeptidase and thrombocytopenia. At 2 months, the objective response rate was 52% (complete response, 28%, and partial response, 24%) by modified Response Evaluation Criteria in Solid Tumours. The median time to progression was 12.1 months (95% CI 7.4 months - not reached); the median overall survival was 24.5 months (95% CI 14.7 months - not reached). Pharmacokinetic analysis demonstrated the ability of DEBs to release idarubicin slowly. Conclusions Using drug-eluting beads, the maximum-tolerated dose of idarubicin was 10 mg per TACE session. Encouraging responses and median time to progression were observed. Further clinical investigations are warranted ( NCT01040559). [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.
- Author
-
Di Martino, V., Crouzet, J., Hillon, P., Thévenot, T., Minello, A., and Monnet, E.
- Subjects
HEPATITIS C ,HEALTH outcome assessment ,ANTIVIRAL agents ,VIROLOGY ,CIRRHOSIS of the liver ,LIVER cancer ,COHORT analysis - Abstract
This population-based study aimed to assess the determinants of the outcome of chronic hepatitis C with analysis of the impact of antiviral therapy with or without sustained virological response (SVR) on cirrhosis decompensation, hepatocellular carcinoma, liver-related and non-liver-related mortality. A total of 1159 HCV-positive patients newly detected between 1994 and 2001 were included. For each outcome, the prognostic effect of patients' baseline characteristics was estimated by time-dependent Cox models using age as the time-scale and adjusting for treatment received during follow-up. The impact of antiviral therapy was assessed by using a propensity score in a sample including 184 patients treated in the first 24 months following diagnosis who were matched to 184 untreated patients. At the end of a 59-month median follow-up, 100 cases of compensated disease, 58 liver cancer and 163 deaths (55 liver related) were recorded. The 5-year rates of decompensated cirrhosis, hepatocellular carcinoma, liver-related and non-liver-related death were 4.4%, 2.7%, 5.0% and 8.9%, respectively. Multivariate analyses identified two variables with pejorative influence: alcohol consumption (RR = 4.29 for CD; RR = 5.76 for HCC; RR = 6.69 for liver-related death; P < 0.0001); HCV diagnosis unrelated to systematic screening (RR = 2.25 for CD; RR = 3.05 for HCC; RR = 4.31 for liver-related death, P < 0.03). In the matched subset, no significant benefit of antiviral therapy was observed. Nevertheless, among the 144 patients who achieved SVR, no death was observed. This population-based study showed substantial rates of decompensated cirrhosis, hepatocellular carcinoma and non-liver-related mortality. Alcohol consumption and absence of systematic screening were significant determinants of poor outcome, whereas treatment did not have significant influence. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. The impact of the prevention programme of hepatitis C over more than a decade: the French experience.
- Author
-
Delarocque-Astagneau, E., Meffre, C., Dubois, F., Pioche, C., Le Strat, Y., Roudot-Thoraval, F., Hillon, P., Silvain, C., Dhumeaux, D., and Desenclos, J. -C.
- Subjects
HEPATITIS C prevention ,HEPATITIS C virus ,VIRAL hepatitis ,HIV-positive persons ,LIVER diseases - Abstract
To assess the impact of the French national hepatitis C prevention programme initiated in 1999, we analysed trends in hepatitis C virus (HCV) prevalence, testing and characteristics of HCV-infected patient at first referral from 1994 to 2006. We used four data sources: Two national population-based sero-prevalence surveys carried out in 1994 and 2004; two surveillance networks, one based on public and private laboratories throughout France and the other on hepatology reference centres, which aim to monitor, respectively, trends of anti-HCV screening and of epidemiological–clinical characteristics of HCV patients at first referral.Between 1994 and 2004, the anti-HCV prevalence for adults aged 20–59 years decreased from 1.05 (95% confidence interval 0.75–1.34) to 0.71 (0.52–0.97). During the same period, those anti-HCV positive with detectable HCV RNA decreased from 81 to 57%, whereas, the proportion of anti-HCV positive persons aware of their status evolved from 24 to 56%. Anti-HCV screening activity increased by 45% from 2000 to 2005, but decreased in 2006 (−10%), while HCV positivity among those tested decreased from 4.3 to 2.9%. The proportion of cirrhosis at first referral remains around 10% between 2001 and 2006, with many patients with excessive alcohol consumption (34.7% among males) or viral co-infections (HIV seropositivity for 5.2% patients). Our analysis indicates that the national programme had a positive impact at the population level through improved prevention, screening and management. There is still a need to identify timely those at risk for earlier interventions, to assess co-morbidities better and for a multidisciplinary approach to HCV management. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
6. Specific phenotype associated with diabetes mellitus secondary to chronic hepatitis C infection.
- Author
-
Poussier A, Lebouvier M, Penfornis A, Di Martino V, Buffier P, Verges B, Hillon P, and Petit JM
- Published
- 2008
- Full Text
- View/download PDF
7. Is the management of hepatitis C patients appropriate? A population-based study.
- Author
-
Hatem, C., Minello, A., Bresson‐Hadni, S., Jooste, V., Evrard, P., Obert, B., Lepage, C., Bonithon‐Kopp, C., Faivre, J., Monnet, E., Miguet, J.‐P., and Hillon, P.
- Subjects
HEPATITIS C ,VIRAL hepatitis ,LIVER diseases ,ANTIVIRAL agents ,VIRUS diseases - Abstract
: In order for hepatitis C patients to receive antiviral treatment, they must reach medical care.: To assess the proportion of patients reaching medical care after hepatitis C diagnosis in a general population (1 006 171 inhabitants) in France.: Between 1994 and 1999, 1508 cases were diagnosed, of which 1251 were eligible for the study.: Two-hundred and two patients did not have any medical care; among them, 55.4% had normal alanine transferase, 58.4% had risk factors related to lifestyle and 22.8% were alcoholics. Amongst the 1049 other patients, 41.6% had a liver biopsy, 25.0% were treated. Treatment was more often carried out in males than in females (OR: 1.59;P = 0.001), and in patients under 65 than in older patients (OR: 2.22;P < 0.008). Among non-treatment reasons, alcoholism (P = 0.001), drug-addiction (P = 0.04) and escaping monitoring (P = 0.04) were more frequent in males than in females, whereas normal alanine transferase was more frequent in females than in males (P = 0.004). Amongst 278 patients with a Metavir score>A1F1, 71 (25.5%) did not undergo treatment.: In a general population, one patient in six did not receive on-going health care; a quarter of patients with a Metavir score>A1F1 did not receive any treatment. These results showed insufficient clinical management, which could compromise the effectiveness of treatment in general population. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
8. Adenoma--carcinoma sequence or "de novo" carcinogenesis? A study of adenomatous remnants in a population-based series of large bowel cancers.
- Author
-
Bedenne, L., Faivre, J., Boutron, M. C., Piard, F., Cauvin, J. M., and Hillon, P.
- Published
- 1992
- Full Text
- View/download PDF
9. Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients.
- Author
-
Mouillot T, Rizk M, Pais de Barros JP, Gilloteau A, Busson A, Bernard-Chabert B, Thiefin G, Barraud H, Bronowicki JP, Richou C, Di Martino V, Doffoel M, Minello A, Latournerie M, Jouve JL, Brondel L, Brindisi MC, Petit JM, Hillon P, and Cottet V
- Subjects
- Aged, Biomarkers blood, Carcinoma, Hepatocellular epidemiology, Case-Control Studies, Female, Humans, Liver Cirrhosis epidemiology, Liver Neoplasms epidemiology, Male, Middle Aged, Odds Ratio, Phospholipids blood, Risk Factors, Carcinoma, Hepatocellular blood, Erythrocyte Membrane chemistry, Fatty Acids blood, Liver Cirrhosis blood, Liver Neoplasms blood
- Abstract
Background: Disturbances in fatty acid (FA) metabolism have been reported in cirrhosis, but the role of FAs in the development of hepatocellular carcinoma (HCC) is still unclear. Biomarkers are a promising means to explore the associations between exogenous intake or endogenous production of FAs and cancer risk., Aim: To estimate the relationship between fatty acid content in erythrocyte membranes and HCC risk in cirrhotic patients METHODS: The "CiRCE" case-control study recruited cirrhotic patients from six French hospitals between 2008 and 2012. Cases were cirrhotic patients with HCC (n = 349); controls were cirrhotic patients without HCC at inclusion (n = 550). FA composition of phospholipids in erythrocyte membranes was determined by high performance gas chromatography. Odds ratios for HCC risk according to FA concentrations were estimated with multivariable logistic regression., Results: HCC patients were older and more often men (P < 0.001). In both groups, saturated FAs represented more than 39% of all FAs in erythrocyte membranes, mono-unsaturated FAs around 14%, and polyunsaturated FAs around 46%. High levels of C15:0 + C17:0, C20:1 n-9, C18:2 n-6 and C20:2 n-6 were associated with higher risk of HCC. The levels of C18:0 and C20:4 n-6 were lower in HCC cases than in controls., Conclusions: The FA composition of erythrocyte membranes differed according to the presence of HCC with higher levels of saturated FAs, linoleic and eicosadienoic acids, and lower levels of stearic and arachidonic acids. These alterations may reflect particular dietary patterns and/or altered FA metabolism. Further investigations are warranted., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
10. Compound heterozygous PKHD1 variants cause a wide spectrum of ductal plate malformations.
- Author
-
Courcet JB, Minello A, Prieur F, Morisse L, Phelip JM, Beurdeley A, Meynard D, Massenet D, Lacassin F, Duffourd Y, Gigot N, St-Onge J, Hillon P, Vanlemmens C, Mousson C, Cerceuil JP, Guiu B, Thevenon J, Thauvin-Robinet C, Jacquemin E, Rivière JB, Michel-Calemard L, and Faivre L
- Subjects
- Adult, Bile Duct Diseases pathology, Bile Ducts, Intrahepatic embryology, Bile Ducts, Intrahepatic pathology, Child, Exome genetics, Female, Genetic Predisposition to Disease, Heterozygote, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Pedigree, Phenotype, Polycystic Kidney, Autosomal Recessive pathology, Prognosis, Young Adult, Bile Duct Diseases genetics, Bile Ducts, Intrahepatic abnormalities, Mutation genetics, Polycystic Kidney, Autosomal Recessive genetics, Receptors, Cell Surface genetics
- Abstract
Ductal plate malformations (DPM) present with a wide phenotypic spectrum comprising Von Meyenburg complexes (VMC), Caroli disease (CD), Caroli syndrome (CS), and autosomal recessive polycystic kidney disease (ARPKD). Variants in PKHD1 are responsible for ARPKD and CS with a high inter- and intra-familial phenotypic variability. Rare familial cases of CD had been reported and exceptional cases of CD are associated with PKHD1 variants. In a family of three siblings presenting with a wide spectrum of severity of DPM, we performed whole exome sequencing and identified two PKHD1 compound heterozygous variants (c.10444G>A; p.Arg3482Cys and c.5521C>T; p.Glu1841Lys), segregating with the symptoms. Two compound heterozygous PKHD1 variants, including one hypomorphic variant, were identified in two other familial cases of DPM with at least one patient presenting with CD. This report widens the phenotypic variability of PKHD1 variants to VMC, and others hepatic bile ducts malformations with inconstant renal phenotype in adults and highlights the important intra-familial phenotypic variability. It also showed that PKHD1 might be a major gene for CD. This work adds an example of the contribution of exome sequencing, not only in the discovery of new genes but also in expanding the phenotypic spectrum of well-known disease-associated genes, using reverse phenotyping., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
11. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
- Author
-
Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, Bouillet B, Brindisi MC, Robin I, Gambert P, Verges B, Cercueil JP, and Hillon P
- Subjects
- Aged, Biomarkers blood, Body Mass Index, Chi-Square Distribution, Cross-Sectional Studies, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 enzymology, Fatty Liver enzymology, Fatty Liver genetics, Female, France, Gene Frequency, Genetic Predisposition to Disease, Homozygote, Humans, Liver pathology, Liver Cirrhosis blood, Liver Cirrhosis enzymology, Liver Cirrhosis pathology, Logistic Models, Magnetic Resonance Spectroscopy, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Odds Ratio, Phenotype, Prospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Diabetes Mellitus, Type 2 genetics, Lipase genetics, Liver enzymology, Liver Cirrhosis genetics, Membrane Proteins genetics, Polymorphism, Genetic
- Abstract
Context: Recently, it has been shown that an allele in the adiponutrin (PNPLA3) gene was strongly associated with increased liver fat content (LFC) and liver fibrosis independent of visceral adiposity and insulin resistance., Objective: In this study, we set out to determine whether the PNPLA3 rs738409 polymorphism was associated with liver fibrosis in unselected patients with type 2 diabetes., Design, Setting and Participants: Two hundred and thirty-four patients with type 2 diabetes were included in this study., Main Outcome Measures: LFC was evaluated using (1) H-MR spectroscopy; fibrosis was measured using the non-invasive FibroTest(®)., Results: Advanced liver fibrosis (stage F2 or above) was observed in 10.2% of the patients while 149 (63.6%) patients had steatosis. The prevalence of steatosis and fibrosis was higher in minor G allele carriers than that in C allele homozygote carriers (70.3 vs 57.1%; P=0.04 and 14.7 vs 7.5%; P=0.07 respectively). In multivariate analysis, the predictive variables for advanced liver fibrosis were age (≥60) (P=0.005), sex (female) (P=0.004) and rs 738409 PNPLA3 polymorphism (P=0.01); body mass index (BMI) and LFC were not associated with liver fibrosis., Conclusions: This study confirms that in patients with type 2 diabetes who were not selected for liver abnormalities, liver fibrosis was related to the rs738409 polymorphism independent of BMI or LFC., (© 2011 John Wiley & Sons A/S.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.